Value of the progesterone test in screening for endometrial pathology in asymptomatic postmenopausal women receiving treatment with tamoxifen

Menopause

Volumn 17, Issue 3, 2010, Pages 487-493

  Lubián López, Daniel María ^a   Fernandez, Yurena González ^a   Rodríguez, Begoña Rodríguez ^a   López, Francisco Martín Orihuela ^a   Delgado, Rafael Comino ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; DIAGNOSTIC ACCURACY; ENDOMETRIAL DISEASE; ENDOMETRIUM ATROPHY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; GOLD STANDARD; HISTOLOGY; HUMAN; HYSTEROSCOPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTION; PROGESTERONE CHALLENGE TEST; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION; VALIDITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BREAST NEOPLASMS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TAMOXIFEN;

EID: 77952251340     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181ca2513     Document Type: Article

References (49)

1. Kinsinger LA, Harris R, Lewis C, Woddell M. Chemoprevention of breast cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:59-69.
2. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat 1998;48:81-85.
3. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen J, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664. (Pubitemid 23137230)
4. Cohen J, Rosen DJD, Altaras M, et al. Tamoxifen treatment in pre-menopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroids overgrowth. Br J Cancer 1994;69:620-621.
5. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294.
6. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992; 69:2961-2964.
7. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 2002;101:58-63.
8. Kavak ZN, Binoz S, Ceyhan N, Pekin S. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients. Acta Obstet Gynecol Scand 2000;79:604-607.
9. Cohen I, Perel E, Tepper R, et al. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients. Breast Cancer Res Treat 1999;53:255-262. (Pubitemid 29209894)
10. Fotiou S, Tserkezoglou A, Hadjieleftheriou G, Apostolikas N, Karydas I, Stravelemos K. Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding. Anticancer Res 1998;18:625-629.
11. Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 1999;54:255-260.
12. Van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343: 448-452.
13. Fisher B, Costantino JP, Redmon CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537. (Pubitemid 24111008)
14. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001;97:855-866.
15. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer (Cochrane review). Cochrane Database Syst Rev 2001;1: CD000486.
16. Currie JL. Tumores malignos del cuerpo uterino. In: Rock JA, Thompson JD, eds. The Linde. Ginecoloǵia Quirúrgica; Edit Panamer-icana. 8th ed. Buenos Aires: Editorial Panamericana;1988:1524-1578.
17. Carlson RW. Overview from a medical oncologist. Semin Oncol 1997; 24:151.
18. American College of Obstetricians and Gynecologists. Committee on Gynecologic Practice. ACOG Committee Opinion 126. Hormone Replacement Therapy in Women Treated for Endometrial Cancer. Washington, DC: American College of Obstetricians and Gynecologists, 1993.
19. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000;22:1-11.
20. Barakat RR. Should women receiving tamoxifen for breast cancer be screened for endometrial biopsy. Cancer Invest 2000;18:796-797.
21. Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 2003;91:154-159.
22. Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000;18: 3464-3470.
23. Runowicz CD. Gynecologic surveillance of women on tamoxifen: first do no harm. J Clin Oncol 2000;18:3457-3458.
24. Marchesoni D, Driul L, Fabiani G, Di Loreto C, Cataldi P, Mozzanega B. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen. Int J Gynaecol Obstet 2001;75:257-262.
25. Fong K, Kung R, Lytwyn A, et al. Endometrial evaluation with trans-vaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology 2001;220: 765-773.
26. Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C, Ranstam J. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res 2000;20:4889-4891.
27. Ito T, Katagiri C, Murata Y, et al. Indication for histological examination of endometrium in breast carcinoma patients receiving ta-moxifen therapy. J Obstet Gynecol Res 2001;27:141-145.
28. Strauss HG, Wolters M, Methfessel G, et al. Significance of endovaginal ultrasonography in assessing tamoxifen-associated changes of the en-dometrium. A prospective study. Acta Obstet Gynecol Scand 2000;79: 679-701.
29. Ballard P, Tetlow R, Richmond I, et al. Errors in the measurement of endometrial depth using transvaginal sonography in postmenopausal women on tamoxifen random error is reduced using saline-instilled so-nography. Ultrasound Obstet Gynecol 2000;15:321-326.
30. Hann LE, Gretz EM, Bach AM, Francis SM. Sonohysterography for evaluation of the endometrium in women treated with tamoxifen. AJR Am J Roentgenol 2001;177:337-342.
31. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-443.
32. Hanna JH, Brady WK, Hill JM, Phillips GL. Detection of postmeno-pausal women at risk for endometrial carcinoma by a progesterone challenge test. Am J Obstet Gynecol 1983;147:872-875.
33. Toppozada MK, Ismail AA, Hamed RS, Ahmed KS, el-Faras A. Progesterone challenge test and estrogen assays in menopausal women with endometrial adenomatous hyperplasia. Int J Gynaecol Obstet 1988; 26:115-119.
34. El-Maraghy MA, el-Badawy N, Wafa GA, Bishai N. Progesterone challenge test in postmenopausal women at high risk. Maturitas. 1994;19: 53-57.
35. Gershenson DM. Cribado de la enfermedad endometrial en las usuarias de tamoxifeno. Ob/Gyn Clin Alert (Ed Española); 2001, 1:33-48.
36. Gambrell RD, Massey FM, Castaneda TA, et al. Use of the progesto-gen challenge test to reduction the risk of endometrial cancer. Obstet Gynecol 1980;55:732-738.
37. Enry R, Isnard S, Boubli L. Progestogen tests after the menopause. Rev Fr Gynecol Obstet 1986;81:195-198.
38. Jaber R. Detection of and screening for endometrial cancer. J Fam Pract 1988;26:67-72.
39. Viel A, Goriaux JL, Rouge JC, et al. Is the progesterone test a gen-eralizable method of screening for neoplasic lesions of the endome-trium? Bull Cancer 1990;77:371-376.
40. Pehlivanov B, Malinova M, Grozdanov G. Progesterone challenge test for evaluation of endometrial hyperplasia in postmenopausal women. Folia Med (Plovdiv) 1998;40:22-25.
41. Malinova M, Pehlivanov B. Transvaginal sonography and progesterone challenge for identifying pathology in postmenopausal women. Int Gynaecol Obstet 1996;52:49-53.
42. Kawabata M, Tsuda H, Kawabata K, et al. Ultrasonography evaluation of the endometrium in postmenopausal women to select the high risk group for endometrial carcinoma of the uterus. Nipón Sanka Fujinka Gakkai Zasshi 1989;41:1512-1516.
43. Pansini F, De Paoli D, Serra MM, et al. Combined use of progesterone challenge test and endometrium thickness evaluated by transvaginal ultrasonography in the preventive management of postmenopausal women. Gynecol Obstet Invest 1992;34:237-239.
44. Ivanov S, Karagozov A, Kurlov T, et al. The early detection and screening of endometrial carcinoma by progesterone test and uterine sonography. Akush Ginekol (Sofiia) 1993;32:24-25.
45. Bortoletto CC, Baracat EC, Goncalves WJ, et al. Transvaginal ultra-sonography and the progestogen challenge test in postmenopausal endometrial evaluation. Int Gynaecol Obstet 1997;58:293-298.
46. Hempel E, Noschel H, Eichhorn KH, et al. Comparison of the progesterone test and uterus sonography and screening procedures in the detection of patients at risk of endometrial cancer. Zentralbl Gynakol 1988;110:597-602.
47. Cuestionario de Ansiedad Estado-Rasgo de Spielberg (STAI). En Manual de Práctica Psiquiátrica. Barcelona, Spain: Edit Masson, 1987
48. Tamoxifen and uterine cancer. ACOG Committee Opinion No. 336. American College of Obstetricians and Gynecologists. Obstet Gynecol 2006;107:1475-1478.
49. Berliere M, Radikov G, Galant C, Piette P, Marbaix E, Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000;36:S35-S36.